ONCrg Congress Insights: 
MPNs at ASCO/EHA 2026 and Beyond

Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline myelofibrosis (MF). All in this wave have faced struggles, selinexor included, with a missed symptom endpoint in Phase III SENTRY. Detailed outcomes reported at ASCO will inform not only the next steps for selinexor, but future development in the field of first-line MF as a whole.

MPNs at ASCO/EHA 26

Antibody Drug Conjugates

Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026  ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]

Non-Hodgkin’s Lymphoma

Excerpt from Custom Post Type Indication: NHL

Myeloproliferative Neoplasms

Excerpt from Custom Post Type Indication: MPNs

Multiple Myeloma

Excerpt from Custom Post Type Indication: MM

Chronic Lymphocytic Leukemia

Excerpt from Custom Post Type Indication: CLL

Acute Myeloid Leukemia

Excerpt from Custom Post Type Indication: AML

Acute Lymphoblastic Leukemia

Excerpt from Custom Post Type Indication: ALL

Cell Therapies

Excerpt from Custom Post Type Indication: Cell Therapies